Precision medicine targeting disrupted IGF signaling in hepatoblastoma

I.M. Quetglas, Roser Pinyol, Daniel Dauch, Anna Portela, Alberto Villanueva, Judit Peix, María Ángeles Moreno de la Higuera, Agrin Moeini, Jessica Zucman‐Rossi, Manel Esteller, Vincenzo Mazzaferro, Lars Zender, Josep M. Llovet

European Journal of Cancer

Article2008

2 DISRUPTION OF IGF SIGNALING IN EARLY HEPATOCELLULAR CARCINOMA AND PRE-CLINICAL EFFICACY OF ANTI-IGF1R BLOCKING THERAPIES

Victoria Tovar, Clara Alsinet, Laia Cabellos, María A. Solé, A. Villanueva, Derek Y. Chiang, Susana Moyano, M. Schwartz, Vincenzo Mazzaferro, Jordi Bruix, Josep M. Llovet

Journal of Hepatology

Precision medicine targeting disrupted IGF signaling in hepatoblastoma

Abstract

Discussion(0)

Related publications

Precision electronic medicine in the brain

Molecular therapies and precision medicine for hepatocellular carcinoma

Translating '–omics' results into precision medicine for hepatocellular carcinoma

466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapies

2 DISRUPTION OF IGF SIGNALING IN EARLY HEPATOCELLULAR CARCINOMA AND PRE-CLINICAL EFFICACY OF ANTI-IGF1R BLOCKING THERAPIES